Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 5,40 € (+24,71 %). La mediana es de 5,24 € (+21,02 %).
| Comprar |
3 |
| Mantener |
7 |
| Vender |
2 |
Noticias Ir al feed de noticias
RxSight unveils turnaround plan and strengthens partnership with Alcon
At the Wells Fargo Healthcare Conference, new CEO Aziz Mottiwala presented a strategic realignment plan to intensify use of the light‑adjustable lens (LAL) among existing surgeons and to double U.S. sales through internal reallocations. The partnership closed in July with Alcon includes a $200 million upfront payment and a 30% royalty on future sales, plus access to Alcon’s sales network. RxSight has about $210 million in cash (excluding the full Alcon payment), high gross margins, and is working on a next‑generation LAL; the company is targeting a return to growth in 2027 but has not provided concrete forecasts. » Más en de.investing.com
RxSight appoints Aziz Mottiwala as president and CEO
RxSight appointed Aziz Mottiwala, effective July 20, as president and chief executive officer; he replaces Dr. Ron Kurtz, who will move to chief medical officer and leave the board of directors, while Mottiwala will be named to the board. Mottiwala joins from Tarsus Pharmaceuticals and brings experience in senior sales and commercial roles in ophthalmology. The stock is under pressure (about −8% last week, −50% over six months) and is trading at $5.25 (market capitalization $216.92 million). The company manufactures the Light Adjustable Lens System and said it would not change its prior financial guidance. » Más en de.investing.com
RxSight cuts 2026 revenue forecast after competitive pressure
RxSight lowered its 2026 revenue forecast to $110–120 million (previously $120–135 million), triggering a roughly 12.9% share price decline. The total revenue outlook of $140–160 million includes $30–40 million from the Alcon collaboration; preliminary Q2 revenues are expected at $32–34 million ( $5–7 million from the Alcon partnership, about $27 million from product sales). The company cited "significant commercial headwinds" and plans to accelerate sales investments while maintaining spending discipline; gross margin guidance was raised to 73–75%, and operating expenses remain at the high end of the $150–160 million range. Cash and equivalents totaled about $209 million as of June 30; RxSight is working on a next generation of Light Adjustable Lens products. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 21,71 M | 16,04 % |
| Beneficio bruto | 15,98 M | 22,60 % |
| Beneficio neto | -14,32 M | 71,24 % |
| EBITDA | -13,48 M | 76,74 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 168,26 M € |
Número de acciones | 41,59 M |
Máximo/mínimo de 52 semanas | 11,78 € - 3,66 € |
| Dividendos | No |
Beta | 1,19 |
Ratio P/E | -3,55 |
Ratio PEG | 0,10 |
Ratio P/B | 0,74 |
Ratio P/S | 1,55 |
Perfil de la empresa
RxSight, Inc., una empresa de tecnología médica, se dedica a la investigación y desarrollo, fabricación y venta de lentes intraoculares ajustables con luz (LAL) utilizadas en la cirugía de cataratas en Estados Unidos y a nivel internacional. Ofrece el sistema RxSight, que permite a los médicos personalizar y mejorar la agudeza visual de los pacientes después de la cirugía de cataratas. El sistema RxSight de la compañía incluye el dispositivo de administración de luz RxSight, un dispositivo de tratamiento con luz de uso en consulta que emite luz UV con un patrón programado para modificar la LAL según la corrección visual necesaria para lograr la visión deseada tras la cirugía de cataratas. Sus principales clientes son los oftalmólogos especialistas en cataratas. La empresa se conocía anteriormente como Calhoun Vision, Inc. y cambió su nombre a RxSight, Inc. en febrero de 2017. RxSight, Inc. se constituyó en 1997 y tiene su sede en Aliso Viejo, California.
| Nombre | RXSIGHT INC. DL -,001 |
| CEO | Aziz Mottiwala |
| Sede | Aliso Viejo,
ca Estados Unidos |
| Sitio web | |
| Sector | Salud |
| Industria | Equipos y suministros sanitarios |
| Salida a bolsa | 30/07/2021 |
| Empleados | 461 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | RXST |